[18F]FES PET/CT in PAH

NCT02899533 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2021-05-18

No results posted yet for this study

Summary

In this study positron emission tomography (PET/CT) imaging will be used to evaluate evaluation of estrogen receptor heterogeneity and functionality in Pulmonary Arterial Hypertension (PAH) using the investigational radiotracer \[18F\]fluoroestradiol (FES).

Conditions

Interventions

DRUG

[18F] FES

\[18F\] FES PET/CT scan, imaging tracer

Sponsors & Collaborators

Principal Investigators

  • David Mankoff, MD, PhD · University of Pennsylvania

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2021-04-06
Completion
2021-04-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02899533 on ClinicalTrials.gov